Clinical Trial: SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

Official Title: A Phase II Open Label Study of the PI3 Kinase (PI-3) Inhibitor, SF1126, in Patients With Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes

Brief Summary:

The purpose of this study is to test the good and bad effects of an experimental drug called SF1126. This drug is being tested in patients whose cancer has not been controlled by available standard therapies and who have certain genes in their tumor.

SF1126 is a drug that inhibits a cell protein called phosphatidyl inositol 3 kinase (PI3K). PI3K is part of signaling pathway that tells cancer cells to grow, survive, invade and metastasize. PI3K also has an important role in the development of blood vessels that are required to support tumor growth. SF1126 is being developed by SignalRx Pharmaceuticals, Inc. It is considered an experimental drug because it is not approved by the FDA for any disease treatment.


Detailed Summary:

SignalRx Pharmaceuticals has developed a pan isoform specific PI-3 inhibitor called SF1126 to treat patients with advanced or metastatic cancer. SF1126 is a conjugate that contains two components: SF1101 (the active drug) and SF1174 (an inactive tetrapeptide RGD targeting moiety)

Both components of SF1126 play key roles in the activity of the drug. SF1101 is a selective inhibitor of certain members of the phosphatidyl inositol 3-kinase (PI-3) family and SF1174 binds selectively to receptors known to be present on neovasculature supporting tumors and on some tumor cells themselves. These components result in a drug designed to be both selective in its activity and targeted in its delivery.

This is an open label Phase II study of SF1126 in adult patients with recurrent or refractory advanced SCCHN with PIK3CA mutation. Treatment cycles (28 days) will consist of SF1126 1110 mg/m2 administered intravenously (IV) twice per week (separated by at least three days) for the first four cycles and then once weekly for subsequent cycles.


Sponsor: Ezra Cohen

Current Primary Outcome: To determine ORR [ Time Frame: 6 months ]

best response of PR or CR observed within 6 months of enrollment


Original Primary Outcome: Same as current

Current Secondary Outcome:

  • To assess treatment-related adverse events as assessed by CTCAE v4.0 [ Time Frame: 4 years ]
  • To assess the effect of SF1126 on time to progression. [ Time Frame: 4 years ]
  • To assess the effect of SF1126 on overall survival. [ Time Frame: 4 years ]
  • To assess disease-related patient-reported outcomes using the EORTC-QLQ- [ Time Frame: 4 years ]


Original Secondary Outcome: Same as current

Information By: University of California, San Diego

Dates:
Date Received: December 7, 2015
Date Started: November 2016
Date Completion: April 2022
Last Updated: December 12, 2016
Last Verified: December 2016